Review



cd66b apc cy7  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd66b apc cy7
    Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + <t>CD66b</t> neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.
    Cd66b Apc Cy7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 63 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd66b apc cy7/product/Miltenyi Biotec
    Average 94 stars, based on 63 article reviews
    cd66b apc cy7 - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination"

    Article Title: Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

    Journal: Cancers

    doi: 10.3390/cancers14184464

    Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + CD66b neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.
    Figure Legend Snippet: Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + CD66b neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.

    Techniques Used: Infection



    Similar Products

    cd66b apc cy7  (Miltenyi Biotec)
    94
    Miltenyi Biotec cd66b apc cy7
    Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + <t>CD66b</t> neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.
    Cd66b Apc Cy7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd66b apc cy7/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cd66b apc cy7 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    antibodies for flow cytometry analysis (cd66b—fitc, cd11b—apc-cy7, cd45—vioblue, cd16—viogreen and cd62l—pe-cy7)  (Thermo Fisher)
    90
    Thermo Fisher antibodies for flow cytometry analysis (cd66b—fitc, cd11b—apc-cy7, cd45—vioblue, cd16—viogreen and cd62l—pe-cy7)
    Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + <t>CD66b</t> neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.
    Antibodies For Flow Cytometry Analysis (Cd66b—Fitc, Cd11b—Apc Cy7, Cd45—Vioblue, Cd16—Viogreen And Cd62l—Pe Cy7), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies for flow cytometry analysis (cd66b—fitc, cd11b—apc-cy7, cd45—vioblue, cd16—viogreen and cd62l—pe-cy7)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    antibodies for flow cytometry analysis (cd66b—fitc, cd11b—apc-cy7, cd45—vioblue, cd16—viogreen and cd62l—pe-cy7) - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + CD66b neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.

    Journal: Cancers

    Article Title: Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

    doi: 10.3390/cancers14184464

    Figure Lengend Snippet: Systemic compositions of myeloid cell subsets. ( A , B ) Percentages of monocytes (CD11b + CD66b neg CD14 + ; red), neutrophils (CD11b + CD66b + CD14 + ; blue) and total granulocytes (CD11b + CD66b + CD14 neg , green), within CD11b + cells. ( C ) Percentage of neutrophils in H-CoV and O-CoV. ( D – F ) Percentages of monocytes (CD11b + CD66b neg CD14 + ), neutrophils (CD11b + CD66b + CD14 + ) and granulocytes (CD11b + CD66b + CD14 neg ) in the indicated groups. Statistical significance was evaluated by the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.

    Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO, San Diego, CA, USA), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi, North Rhine-Westphalia, Germany), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

    Techniques: Infection